AU2018280741B2 - Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss - Google Patents

Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss Download PDF

Info

Publication number
AU2018280741B2
AU2018280741B2 AU2018280741A AU2018280741A AU2018280741B2 AU 2018280741 B2 AU2018280741 B2 AU 2018280741B2 AU 2018280741 A AU2018280741 A AU 2018280741A AU 2018280741 A AU2018280741 A AU 2018280741A AU 2018280741 B2 AU2018280741 B2 AU 2018280741B2
Authority
AU
Australia
Prior art keywords
day
weeks
patient
days
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018280741A
Other languages
English (en)
Other versions
AU2018280741A1 (en
Inventor
Jean-Pierre Gotteland
Ernest Loumaye
Oliver Pohl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kissei Pharmaceutical Co Ltd
Original Assignee
Kissei Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical Co Ltd filed Critical Kissei Pharmaceutical Co Ltd
Publication of AU2018280741A1 publication Critical patent/AU2018280741A1/en
Assigned to KISSEI PHARMACEUTICAL CO., LTD. reassignment KISSEI PHARMACEUTICAL CO., LTD. Request for Assignment Assignors: ObsEva S.A.
Application granted granted Critical
Publication of AU2018280741B2 publication Critical patent/AU2018280741B2/en
Priority to AU2024201694A priority Critical patent/AU2024201694A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2018280741A 2017-06-05 2018-06-05 Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss Active AU2018280741B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024201694A AU2024201694A1 (en) 2017-06-05 2024-03-14 Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762515232P 2017-06-05 2017-06-05
US62/515,232 2017-06-05
PCT/EP2018/064767 WO2018224497A1 (en) 2017-06-05 2018-06-05 Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024201694A Division AU2024201694A1 (en) 2017-06-05 2024-03-14 Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss

Publications (2)

Publication Number Publication Date
AU2018280741A1 AU2018280741A1 (en) 2020-01-30
AU2018280741B2 true AU2018280741B2 (en) 2023-12-21

Family

ID=62636157

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018280741A Active AU2018280741B2 (en) 2017-06-05 2018-06-05 Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
AU2024201694A Abandoned AU2024201694A1 (en) 2017-06-05 2024-03-14 Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024201694A Abandoned AU2024201694A1 (en) 2017-06-05 2024-03-14 Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss

Country Status (18)

Country Link
US (2) US11759464B2 (https=)
EP (2) EP3634419B1 (https=)
JP (2) JP7292566B2 (https=)
KR (1) KR102884301B1 (https=)
CN (1) CN110996957A (https=)
AU (2) AU2018280741B2 (https=)
CA (1) CA3066188A1 (https=)
DK (1) DK3634419T3 (https=)
EA (1) EA201992812A1 (https=)
ES (1) ES3018358T3 (https=)
FI (1) FI3634419T3 (https=)
HR (1) HRP20250390T1 (https=)
HU (1) HUE070907T2 (https=)
MX (2) MX2023013582A (https=)
PL (1) PL3634419T3 (https=)
PT (1) PT3634419T (https=)
SG (1) SG11201911599XA (https=)
WO (1) WO2018224497A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL241595B2 (en) 2013-03-15 2025-10-01 Abbvie Inc Composition for use in methods of treating heavy menstrual bleeding associated with uterine fibroids
SG11201911598WA (en) 2017-06-05 2020-01-30 ObsEva SA Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
SG11201911599XA (en) 2017-06-05 2020-01-30 ObsEva SA Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
AU2018419533A1 (en) 2018-04-19 2020-11-12 Abbvie Inc. Methods of treating heavy menstrual bleeding
EP3829584A4 (en) * 2018-08-01 2022-06-08 Abbvie Inc. DOSAGE SCHEDULES FOR ELAGOLIX
CA3117092A1 (en) 2018-10-29 2020-05-07 ObsEva S.A. Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
SG11202104053TA (en) * 2018-11-07 2021-05-28 ObsEva SA Compositions and methods for the treatment of estrogen-dependent disorders
AU2020325721A1 (en) * 2019-08-08 2022-03-03 ObsEva S.A. GnRH antagonists for the treatment of estrogen-dependent disorders
AU2020325655B2 (en) * 2019-08-08 2025-09-11 Kissei Pharmaceutical Co., Ltd. Compositions and methods for the treatment of estrogen-dependent disorders
KR20210155350A (ko) 2020-06-15 2021-12-22 한상왕 녹차 추출물 및 비타민 d3를 유효성분으로 포함하는 자궁근종 개선용 조성물
CN115232144B (zh) * 2021-04-22 2024-04-02 长春金赛药业有限责任公司 含氮稠环类衍生物、药物组合物及其制备方法和应用
KR102738115B1 (ko) 2024-03-25 2024-12-05 한상왕 자궁근종 예방, 개선 또는 치료용 약학 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2535342A1 (en) * 2010-02-10 2012-12-19 Kissei Pharmaceutical Co., Ltd. Salt of fused heterocyclic derivative and crystal thereof
JP2016513708A (ja) * 2013-03-15 2016-05-16 アッヴィ・インコーポレイテッド 月経出血過多および子宮類線維腫の処置に使用するための組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109171B2 (en) * 2000-02-28 2006-09-19 Praecis Pharmaceuticals Inc. Methods for treating FSH related conditions with GnRH antagonists
PL1939204T6 (pl) * 2005-10-19 2024-03-25 Kissei Pharmaceutical Co., Ltd. Skondensowana pochodna heterocykliczna, zawierająca ją kompozycja oraz jej zastosowanie medyczne
WO2014042176A1 (ja) 2012-09-14 2014-03-20 キッセイ薬品工業株式会社 縮合複素環誘導体の製造方法およびその製造中間体
UA123114C2 (uk) 2016-08-08 2021-02-17 Кіссеі Фармасьютікал Ко., Лтд. СПОСІБ ЛІКУВАННЯ ЕНДОМЕТРІОЗУ 3-[2-ФТОР-5-(2,3-ДИФТОР-6-МЕТОКСИБЕНЗИЛОКСИ)-4-МЕТОКСИФЕНІЛ]-2,4-ДІОКСО-1,2,3,4-ТЕТРАГІДРОТІЄНО[3,4-d]ПІРИМІДИН-5-КАРБОНОВОЮ КИСЛОТОЮ
EP3518933B2 (en) 2016-09-30 2025-02-26 Sumitomo Pharma Switzerland GmbH Methods of treating uterine fibroids and endometriosis
SG11201911598WA (en) 2017-06-05 2020-01-30 ObsEva SA Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
SG11201911599XA (en) 2017-06-05 2020-01-30 ObsEva SA Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
SG11202104053TA (en) 2018-11-07 2021-05-28 ObsEva SA Compositions and methods for the treatment of estrogen-dependent disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2535342A1 (en) * 2010-02-10 2012-12-19 Kissei Pharmaceutical Co., Ltd. Salt of fused heterocyclic derivative and crystal thereof
JP2016513708A (ja) * 2013-03-15 2016-05-16 アッヴィ・インコーポレイテッド 月経出血過多および子宮類線維腫の処置に使用するための組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARCHER ET AL: "Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study", FERTILITY AND STERILITY, 01 Jun 2017, vol. 108, no. 1, pg. 152. *
OBSEVA: "Annual Report 2016". Published 21 April 2017. *

Also Published As

Publication number Publication date
KR102884301B1 (ko) 2025-11-11
MX2019014482A (es) 2020-08-17
EA201992812A1 (ru) 2020-05-21
EP4509173A3 (en) 2025-06-04
HRP20250390T1 (hr) 2025-05-23
AU2024201694A1 (en) 2024-04-04
PL3634419T3 (pl) 2025-06-09
US20200179390A1 (en) 2020-06-11
US20240000785A1 (en) 2024-01-04
JP2020522525A (ja) 2020-07-30
US11759464B2 (en) 2023-09-19
JP7485815B2 (ja) 2024-05-16
HUE070907T2 (hu) 2025-07-28
DK3634419T3 (da) 2025-03-31
CN110996957A (zh) 2020-04-10
JP2023078315A (ja) 2023-06-06
JP7292566B2 (ja) 2023-06-19
EP4509173A2 (en) 2025-02-19
AU2018280741A1 (en) 2020-01-30
EP3634419B1 (en) 2025-01-29
FI3634419T3 (fi) 2025-05-02
PT3634419T (pt) 2025-04-04
ES3018358T3 (es) 2025-05-16
EP3634419A1 (en) 2020-04-15
KR20200024797A (ko) 2020-03-09
MX2023013582A (es) 2024-04-16
CA3066188A1 (en) 2018-12-13
WO2018224497A1 (en) 2018-12-13
SG11201911599XA (en) 2020-01-30

Similar Documents

Publication Publication Date Title
US20240000785A1 (en) Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
US20240293414A1 (en) Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
WO2020094698A2 (en) Compositions and methods for the treatment of estrogen-dependent disorders
AU2020325721A1 (en) GnRH antagonists for the treatment of estrogen-dependent disorders
WO2021023877A2 (en) Compositions and methods for the treatment of estrogen-dependent disorders
EP3873465B1 (en) Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
HK40116843A (en) Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
HK40027583B (en) Dosing regimen comprising a gonadotropin-releasing hormone antagonist for treating uterine fibroids and reducing menstrual blood loss
HK40027583A (en) Dosing regimen comprising a gonadotropin-releasing hormone antagonist for treating uterine fibroids and reducing menstrual blood loss
EA049129B1 (ru) Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения миомы матки и уменьшения менструальной кровопотери
HK40059353B (en) Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
HK40059353A (en) Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: KISSEI PHARMACEUTICAL CO., LTD.

Free format text: FORMER APPLICANT(S): OBSEVA S.A.

FGA Letters patent sealed or granted (standard patent)